GeneDx stock slips premarket as analysts trim targets after 2025 results and 2026 outlook
GeneDx Holdings shares fell 0.5% in premarket trading Tuesday after the company reiterated its 2026 outlook and reported 2025 revenue of $427.5 million. The company disclosed a material weakness in IT controls, with Ernst & Young issuing an adverse opinion on internal financial reporting. BTIG and TD Cowen both cut price targets but kept Buy ratings. GeneDx ended 2025 with $172.3 million in cash.
